The State of Psychedelics (Part 2): Dr. Rachel Yehuda and Zach Haigney (live recording at Soho House)
Business Trip, a podcast about the business of psychedelics
Welcome back to Business Trip, a podcast about the business of psychedelics! 🍄
In this week’s special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. This is part 2 of a moderated panel recorded in front of a live audience, with part 1 released in June 2022. If you haven’t listened to the 1st episode yet, you can find it here.
Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research at the US Veterans Affairs Medical Center and serves as Director at the Mental Health at the James J. Peters VA Medical Center. She is also the Director of the Center for Psychedelic Psychotherapy and Trauma Research at the Icahn School of Medicine at Mount Sinai Hospital and Professor of Psychiatry and Neuroscience. Zach Haigney writes the Trip Report by Beckley Waves, a newsletter about the science, policy, and business of psychedelics.
In this episode, we discuss:
The potential of MDMA vs. psilocybin-assisted therapy for PTSD
The hype vs. the science of current psychedelic clinical trials
Psychedelic legislation approvals in Oregon and Colorado
The importance of harm reduction measures to prevent adverse events
Listen to the episode here, on Spotify or Apple Podcasts.
When you’re done listening, tweet at us @businesstripfm to share your thoughts!
Business Trip is a podcast about psychedelic startups. Each episode features a new company in the field, ranging from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem.
Business Trip is produced by Greg Kubin and Matias Serebrinsky — we’re partners at PsyMed Ventures, advocates of the healing powers of psychedelic medicine.
Thanks for listening,
💖 Know someone who would enjoy Business Trip?